# Vikas Datt

> Vikas Datt is a venture - series unknown investor at CerraCap Ventures backing Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [CerraCap Ventures](https://shizune.co/investors/profile/cerracap-ventures)
- Total investments: 5
- Last investment: Jul 2026
- Lead investor: 80%
- Last updated: Aug 2026

Vikas Datt is a Managing Partner of CerraCap Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Security | 1 | 20% |
| Software | 1 | 20% |
| Life Science | 1 | 20% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 3 | 60% |
| Seed | 2 | 40% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Israel | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MazeBolt | MazeBolt ensures business continuity for global enterprises by validating their DDoS defenses – without the need for maintenance windows. RADAR’s core patented technology continuously runs thousands of nondisruptive simulations, allowing organizations to identify and remediate critical vulnerabilities in their DDoS defenses and configurations, Thisresults in measurable reduction in DDoS risk and stronger regulatory compliance – while preventing the operational, reputational, and financial damages caused by DDoS attacks. |  | Venture - Series Unknown | Jul 07, 2026 |  |
| Nephronomics | Nephronomics is a precision-medicine biotech company focused on cardio-kidney-metabolic (CKM) and primary renal diseases, using large-scale clinical and genomic data combined with AI to discover and develop targeted therapies. |  | Seed | Apr 21, 2026 |  |
| OpsMx | OpsMx is Continuous Delivery and Continuous Verification Company with a vision of “ Delivering software without any human intervention”. |  | Venture - Series Unknown | May 28, 2024 |  |
| Proxtera | Proxtera is a trading network platform designed to facilitate cross-border trade and uplift small and medium enterprises. It uses artificial intelligence to discover prices and sales opportunities, access supply chains, and utilize digital and financial technologies. |  | Seed | Mar 16, 2023 |  |
| Totient | Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble themost potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts. |  | Venture - Series Unknown | Jan 05, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Ant Group](https://shizune.co/investors/profile/ant-group) — VC Fund, 1 deal together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 1 deal together
- [s16vc](https://shizune.co/investors/profile/s16vc) — VC Fund, 1 deal together

## About CerraCap Ventures

VC Fund · Costa Mesa, United States

They invest in disruptive companies with potential to dominate global markets. They look for companies and entrepreneurs with fundamentally strong business model. They take the time and effort to understand each idea and decide on its merits and potential through Their comprehensive evaluation process.

5 contacts available at CerraCap Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Nikki Arora | Partner/ General Partner | https://shizune.co/investors/profile/nikki-arora |
| Jon Soberg | Venture Partner | https://shizune.co/investors/profile/jon-soberg |
| Ritesh Agarwal | Managing Director | https://shizune.co/investors/profile/ritesh-agarwal-f960 |
| Saurabh Ranjan | Founder & Managing Partner | https://shizune.co/investors/profile/saurabh-ranjan |
| Vikas Datt | Managing Partner | https://shizune.co/investors/profile/vikas-datt |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Vikas Datt invest in?

Vikas Datt invests primarily in Biotechnology, Medical and Security startups, most often at Venture - Series Unknown and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Vikas Datt last invest?

The most recent investment recorded for Vikas Datt closed in Jul 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co